Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models
- Supplementary File 1:
PDF-Document (PDF, 1086 KiB)
Sartori, A.; Corno, C.; De Cesare, M.; Scanziani, E.; Minoli, L.; Battistini, L.; Zanardi, F.; Perego, P. Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models. Cancers 2019, 11, 531. https://doi.org/10.3390/cancers11040531
Sartori A, Corno C, De Cesare M, Scanziani E, Minoli L, Battistini L, Zanardi F, Perego P. Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models. Cancers. 2019; 11(4):531. https://doi.org/10.3390/cancers11040531
Chicago/Turabian StyleSartori, Andrea; Corno, Cristina; De Cesare, Michelandrea; Scanziani, Eugenio; Minoli, Lucia; Battistini, Lucia; Zanardi, Franca; Perego, Paola. 2019. "Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models" Cancers 11, no. 4: 531. https://doi.org/10.3390/cancers11040531